|
ES2248581T3
(es)
|
2001-03-12 |
2006-03-16 |
Intercept Pharmaceuticals, Inc. |
Esteroides como agonistas de fxr.
|
|
GB0302094D0
(en)
|
2003-01-29 |
2003-02-26 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
GB0324269D0
(en)
|
2003-10-16 |
2003-11-19 |
Pharmagene Lab Ltd |
EP4 receptor antagonists
|
|
PL1734970T3
(pl)
*
|
2004-03-12 |
2015-05-29 |
Intercept Pharmaceuticals Inc |
Leczenie zwłóknienia z zastosowaniem ligandów FXR
|
|
US10987362B2
(en)
|
2004-03-12 |
2021-04-27 |
Intercept Pharmaceuticals, Inc. |
Treatment of fibrosis using FXR ligands
|
|
ITMI20050912A1
(it)
|
2005-05-19 |
2006-11-20 |
Erregierre Spa |
Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici
|
|
US7618956B2
(en)
|
2005-05-31 |
2009-11-17 |
The Gillette Company |
Reduction of hair growth
|
|
WO2007076260A2
(en)
|
2005-12-19 |
2007-07-05 |
Smithkline Beecham Corporation |
Farnesoid x receptor agonists
|
|
CA2640476A1
(en)
*
|
2006-02-03 |
2007-08-16 |
Eli Lilly And Company |
Compounds and methods for modulating fx-receptors
|
|
CN101448791B
(zh)
|
2006-05-24 |
2011-11-16 |
伊莱利利公司 |
Fxr激动剂
|
|
TW200812982A
(en)
|
2006-05-24 |
2008-03-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
EP1886685A1
(en)
|
2006-08-11 |
2008-02-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
|
|
EP1894924A1
(en)
*
|
2006-08-29 |
2008-03-05 |
Phenex Pharmaceuticals AG |
Heterocyclic FXR binding compounds
|
|
EP1894928A1
(en)
*
|
2006-08-29 |
2008-03-05 |
PheneX Pharmaceuticals AG |
Heterocyclic fxr binding compounds
|
|
CL2007003035A1
(es)
*
|
2006-10-24 |
2008-05-16 |
Smithkline Beechman Corp |
Compuestos derivados de isoxazol sustituidos, agonistas de receptores farnesoid x; procedimiento de preparacion; composicion farmaceutica que lo comprende; y uso del compuesto en el tratamiento de la obesidad, diabetes mellitus, fibrosis en organos,
|
|
KR101555716B1
(ko)
|
2007-01-19 |
2015-09-25 |
인터셉트 파마슈티컬즈, 인크. |
Ｔｇｒ5 조절제로서의 23-치환 담즙산 및 이의 사용 방법
|
|
KR20100038102A
(ko)
*
|
2007-06-13 |
2010-04-12 |
글락소스미스클라인 엘엘씨 |
파네소이드 ｘ 수용체 작용제
|
|
MX2009013946A
(es)
*
|
2007-07-02 |
2010-03-10 |
Glaxosmithkline Llc |
Agonistas del receptor de farnesoide x.
|
|
TW200906823A
(en)
|
2007-07-16 |
2009-02-16 |
Lilly Co Eli |
Compounds and methods for modulating FXR
|
|
WO2009012400A2
(en)
*
|
2007-07-19 |
2009-01-22 |
University Of Southern California |
Orally administered peptides to improve or prevent hepatic fibrosis
|
|
US7902201B2
(en)
|
2007-12-04 |
2011-03-08 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyrazine derivatives
|
|
US7943619B2
(en)
|
2007-12-04 |
2011-05-17 |
Hoffmann-La Roche Inc. |
Isoxazolo-pyridazine derivatives
|
|
KR101175859B1
(ko)
|
2007-12-04 |
2012-08-24 |
에프. 호프만-라 로슈 아게 |
이속사졸로-피라진 유도체
|
|
US20100324075A1
(en)
*
|
2007-12-21 |
2010-12-23 |
University Of Cincinnati |
Therapeutic use of carboxyl ester lipase inhibitors
|
|
EP2128158A1
(en)
|
2008-05-26 |
2009-12-02 |
Phenex Pharmaceuticals AG |
Heterocyclic cyclopropyl-substituted FXR binding compounds
|
|
WO2010014836A2
(en)
|
2008-07-30 |
2010-02-04 |
Intercept Pharmaceuticals, Inc. |
Tgr5 modulators and methods of use thereof
|
|
NZ592603A
(en)
*
|
2008-10-21 |
2013-02-22 |
Metabolex Inc |
Aryl gpr120 receptor agonists and uses thereof
|
|
DK2698375T3
(en)
|
2008-11-19 |
2018-05-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulators and methods for using them
|
|
TW201033201A
(en)
|
2009-02-19 |
2010-09-16 |
Hoffmann La Roche |
Isoxazole-isoxazole and isoxazole-isothiazole derivatives
|
|
US8389550B2
(en)
|
2009-02-25 |
2013-03-05 |
Hoffmann-La Roche Inc. |
Isoxazoles / O-pyridines with ethyl and ethenyl linker
|
|
US20100280019A1
(en)
|
2009-04-30 |
2010-11-04 |
Roland Jakob-Roetne |
Isoxazoles
|
|
CA2759598C
(en)
|
2009-05-05 |
2017-09-12 |
F. Hoffmann-La Roche Ag |
Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders
|
|
JP5460858B2
(ja)
|
2009-05-05 |
2014-04-02 |
エフ．ホフマン−ラ ロシュ アーゲー |
イソオキサゾール−ピラゾール誘導体
|
|
CA2760597C
(en)
|
2009-05-05 |
2017-08-22 |
F. Hoffmann-La Roche Ag |
Isoxazole-pyridazine derivatives
|
|
KR101367012B1
(ko)
|
2009-05-05 |
2014-03-14 |
에프. 호프만-라 로슈 아게 |
이속사졸-피리딘 유도체
|
|
BRPI1013766A2
(pt)
|
2009-05-07 |
2016-04-05 |
Hoffmann La Roche |
"derivados de isoxazol-piridina como moduladores de gaba"
|
|
EP2289883A1
(en)
|
2009-08-19 |
2011-03-02 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
MX2012014273A
(es)
|
2010-06-07 |
2013-03-22 |
Novomedix Llc |
Compuestos furanilo y su uso.
|
|
CU24152B1
(es)
*
|
2010-12-20 |
2016-02-29 |
Irm Llc |
1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
|
|
EP2545964A1
(en)
|
2011-07-13 |
2013-01-16 |
Phenex Pharmaceuticals AG |
Novel FXR (NR1H4) binding and activity modulating compounds
|
|
WO2013037482A1
(en)
|
2011-09-15 |
2013-03-21 |
Phenex Pharmaceuticals Ag |
Farnesoid x receptor agonists for cancer treatment and prevention
|
|
US8785435B2
(en)
|
2011-10-20 |
2014-07-22 |
Hoffmann-La Roche Inc. |
Solid forms
|
|
US9982008B2
(en)
|
2012-06-19 |
2018-05-29 |
Intercept Pharmaceuticals, Inc. |
Preparation and uses of obeticholic acid
|
|
SI3336097T1
(sl)
|
2012-06-19 |
2021-07-30 |
Intercept Pharmaceuticals, Inc. |
Priprava nekristalinične oblike obetiholne kisline
|
|
DK3043865T3
(da)
|
2013-09-11 |
2021-02-01 |
Univ Claude Bernard Lyon |
Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion
|
|
US10301268B2
(en)
*
|
2014-03-13 |
2019-05-28 |
The Salk Institute For Biological Studies |
Analogs of fexaramine and methods of making and using
|
|
EP3006939A1
(en)
|
2014-10-06 |
2016-04-13 |
Gilead Sciences, Inc. |
Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation
|
|
US10208081B2
(en)
|
2014-11-26 |
2019-02-19 |
Enanta Pharmaceuticals, Inc. |
Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
|
EP3034501A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Hydroxy containing FXR (NR1H4) modulating compounds
|
|
EP3034499A1
(en)
|
2014-12-17 |
2016-06-22 |
Gilead Sciences, Inc. |
Novel FXR (NR1H4) modulating compounds
|
|
TWI698430B
(zh)
|
2015-02-13 |
2020-07-11 |
南北兄弟藥業投資有限公司 |
三環化合物及其在藥物中的應用
|
|
WO2016161003A1
(en)
|
2015-03-31 |
2016-10-06 |
Enanta Phamraceuticals, Inc. |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
|
ES2862194T3
(es)
*
|
2016-02-22 |
2021-10-07 |
Novartis Ag |
Métodos para usar agonistas del FXR
|
|
WO2017189663A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
US10080741B2
(en)
|
2016-04-26 |
2018-09-25 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
WO2017189651A1
(en)
|
2016-04-26 |
2017-11-02 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201150A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
WO2017201152A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
WO2017201155A1
(en)
|
2016-05-18 |
2017-11-23 |
Enanta Pharmaceuticals, Inc. |
lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF
|
|
US10772813B2
(en)
|
2016-06-03 |
2020-09-15 |
Colradel, LLC |
Compositions and methods of administering a colchicine based topical composition for the prevention of radiation fibrosis
|
|
CA3252823A1
(en)
|
2016-06-13 |
2025-02-25 |
Gilead Sciences, Inc. |
Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds
|
|
MX385718B
(es)
|
2016-06-13 |
2025-03-18 |
Gilead Sciences Inc |
Compuestos moduladores de fxr (nr1h4).
|
|
TW201808283A
(zh)
|
2016-08-05 |
2018-03-16 |
廣東東陽光藥業有限公司 |
含氮三環化合物及其在藥物中的應用
|
|
US10414048B2
(en)
|
2016-09-14 |
2019-09-17 |
Faro Technologies, Inc. |
Noncontact safety sensor and method of operation
|
|
US10450306B2
(en)
|
2016-10-04 |
2019-10-22 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as FXR agonists and methods of use thereof
|
|
WO2018081285A1
(en)
|
2016-10-26 |
2018-05-03 |
Enanta Pharmaceuticals, Inc. |
Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof
|
|
KR20190117632A
(ko)
|
2017-02-21 |
2019-10-16 |
장피트 |
Ppar 효현제와 fxr 효현제의 병용
|
|
PT3600309T
(pt)
|
2017-03-28 |
2022-10-03 |
Gilead Sciences Inc |
Combinações terapêuticas para o tratamento de doenças hepáticas
|
|
WO2018178260A1
(en)
|
2017-03-30 |
2018-10-04 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses
|
|
PL3612520T3
(pl)
*
|
2017-04-12 |
2022-03-21 |
Il Dong Pharmaceutical Co., Ltd. |
Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania
|
|
CN111278817B
(zh)
|
2017-11-01 |
2023-05-16 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的多环化合物
|
|
AU2018360575A1
(en)
|
2017-11-01 |
2020-06-18 |
Bristol-Myers Squibb Company |
Alkene spirocyclic compounds as farnesoid X receptor modulators
|
|
CN111511731B
(zh)
|
2017-11-01 |
2023-05-23 |
百时美施贵宝公司 |
作为法尼醇x受体调节剂的烯烃化合物
|
|
WO2019118571A1
(en)
|
2017-12-12 |
2019-06-20 |
Enanta Pharmaceuticals, Inc. |
Isoxazole analogs as fxr agonists and methods of use thereof
|
|
CN110128432B
(zh)
|
2018-02-02 |
2021-03-02 |
广东东阳光药业有限公司 |
含氮三环化合物及其在药物中的应用
|
|
US10829486B2
(en)
|
2018-02-14 |
2020-11-10 |
Enanta Pharmacueticals, Inc. |
Isoxazole derivatives as FXR agonists and methods of use thereof
|
|
IT201800007265A1
(it)
*
|
2018-07-17 |
2020-01-17 |
|
Isossazoli come agonisti del recettore fxr
|
|
EP3911647B1
(en)
|
2019-01-15 |
2023-12-13 |
Gilead Sciences, Inc. |
Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same
|
|
CA3233305A1
(en)
|
2019-02-19 |
2020-08-27 |
Gilead Sciences, Inc. |
Solid forms of fxr agonists
|
|
WO2020231917A1
(en)
|
2019-05-13 |
2020-11-19 |
Enanta Pharmaceuticals, Inc. |
Isoxazole derivatives as fxr agonists and methods of use thereof
|
|
CN114008040B
(zh)
*
|
2019-06-14 |
2024-09-10 |
南京瑞捷医药科技有限公司 |
用于调节fxr的化合物
|
|
KR20220035365A
(ko)
|
2019-07-18 |
2022-03-22 |
엔요 파마 |
인터페론의 부작용을 감소시키는 방법
|
|
EP4048399A4
(en)
*
|
2019-10-24 |
2023-10-25 |
ONO Pharmaceutical Co., Ltd. |
INHIBITORS OF TREK (TWIK-ASSOCIATED K + CHANNELS) CHANNEL FUNCTION
|
|
WO2021108974A1
(en)
|
2019-12-03 |
2021-06-10 |
Gannex Pharma Co., Ltd |
Compounds for modulating activity of fxr and uses thereof
|
|
IL293892A
(en)
|
2020-01-15 |
2022-08-01 |
Inserm Institut National De La Sant? Et De La Rech M?Dicale |
Use of fxr agonists for treating an infection by hepatitis d virus
|
|
JP2024502673A
(ja)
|
2021-01-14 |
2024-01-22 |
ウエヌイグレックオ・ファーマ |
Ｈｂｖ感染の処置のためのｆｘｒアゴニストとｉｆｎの相乗効果
|
|
JP2024517181A
(ja)
|
2021-04-28 |
2024-04-19 |
ウエヌイグレックオ・ファーマ |
組合せ治療としてｆｘｒアゴニストを使用するｔｌｒ３アゴニストの効果の強い増強
|
|
WO2023090858A1
(ko)
*
|
2021-11-17 |
2023-05-25 |
일동제약(주) |
아이속사졸 유도체의 제조 방법 및 그의 중간체
|